Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novartis highlights benefits of new cystic fibrosis treatment

Novartis highlights benefits of new cystic fibrosis treatment

21st June 2010

Novartis has underlined the potential advantages of tobramycin inhalation powder (TIP) as a treatment for conditions experienced by cystic fibrosis (CF) patients.

The pharmaceutical company has published data from a phase III clinical trial, which shows that TIP can offer a similar level of efficacy to atobramycin inhalation solution when treating Pseudomonas aeruginosa infections among CF sufferers.

However, TIP was shown to offer superior performance in terms of convenience and satisfaction, reducing the time taken to administer treatment by 72 per cent.

Dr David Morris, global head of development of the respiratory franchise at Novartis, said the data was important due to the unmet need for new treatment options in this area.

He added: “Novartis is committed to researching and developing effective therapies for serious diseases with limited treatment options such as cystic fibrosis and these latest data further reinforce this approach.”

Last week, Novartis published data from a UK-based clinical trial of Zometa, demonstrating its efficacy in the treatment of multiple myeloma.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.